COO on Nasdaq

The Cooper Companies

Logo: The Cooper Companies, Inc., Public domain, via Wikimedia Commons5

American medical device company

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 19, 2026.

Overview

$4.1BRevenue, fiscal 20256
$374.9MNet income, fiscal 20256
1958Founded1

Compare with Bausch & Lomb, National Vision Holdings, Inc. or Alcon, or pick any stock.

  • TickerCOO on Nasdaq1
  • Industrymedical device1
  • HeadquartersSan Ramon1
  • Websitewww.coopercos.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address6101 Bollinger Canyon Road, Suite 500, San Ramon, Ca 945837
  • Filer categoryLarge accelerated filer7
  • LEIQJKMVPIGLH7530PCUE204
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O THE PRENTICE-HALL CORPORATION SYSTEM, INC., 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 8881324

See how the biggest companies compare on our leaderboards

The Cooper Companies, Inc., branded as CooperCompanies, is a global medical device company headquartered in San Ramon, California. The company consists of two business units, CooperVision (CVI) which manufactures contact lenses, and CooperSurgical (CSI), which manufactures medical devices and fertility and genomic products for the women's healthcare market.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

65.5%Gross margin6
16.7%Operating margin6
9.2%Net margin6
5.1%Revenue growth, 20256
4.6%Return on equity6
0.30×Debt to equity6
$433.7MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

CooperVision brought in 34% of the revenue The Cooper Companies broke down this way in fiscal 2025.

  1. CooperVision$2.7B634%up 5% from 2024
  2. Coopervision$2.7B634%up 5% from 2024
  3. CooperSurgical$1.3B616%up 5% from 2024
  4. Coopersurgical$1.3B616%up 5% from 2024
Business segments by year
Business segments202320242025
CooperVision$2.4B$2.6B$2.7B
Coopervision$2.4B$2.6B$2.7B
CooperSurgical$1.2B$1.3B$1.3B
Coopersurgical$1.2B$1.3B$1.3B

Regions

United States brought in 50% of the revenue The Cooper Companies broke down this way in fiscal 2025.

  1. United States$2.1B650%up 4% from 2024
  2. Europe$1.3B631%up 8% from 2024
  3. Rest Of The World$785.2M619%up 1% from 2024
Regions by year
Regions202320242025
United States$1.8B$2.0B$2.1B
Europe$1.0B$1.2B$1.3B
Rest Of The World$739.8M$773.6M$785.2M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue34¢$1.4B
  • Research and development4¢$172.2M
  • Selling, general and admin40¢$1.6B
  • Other costs8¢$315.6M
  • Income tax5¢$191.6M
  • Profit9¢$374.9M

Out of $4.1B in revenue.6

Where each dollar of operating cash went, fiscal 2025

  • Capital spending46¢$362.4M
  • Share buybacks36¢$290.1M
  • Kept or used elsewhere18¢$143.6M

Out of $796.1M of cash from operations.6

Financial statements

Revenue9101112136$4.1B in 2025+62% since 2018
0$2.0B$4.0B$6.0B2018: $2.5B$2.5B20182019: $2.7B$2.7B2019+5%2020: $2.4B$2.4B2020−8%2021: $2.9B$2.9B2021+20%2022: $3.3B$3.3B2022+13%2023: $3.6B$3.6B2023+9%2024: $3.9B$3.9B2024+8%2025: $4.1B$4.1B2025+5%
Gross profit9101112136$2.7B in 2025+64% since 2018
0$1.0B$2.0B$3.0B2018: $1.6B$1.6B20182019: $1.8B$1.8B2019+8%2020: $1.5B$1.5B2020−13%2021: $2.0B$2.0B2021+27%2022: $2.1B$2.1B2022+9%2023: $2.4B$2.4B2023+10%2024: $2.6B$2.6B2024+10%2025: $2.7B$2.7B2025+3%
Operating income9101112136$682.9M in 2025+69% since 2018
0$200.0M$400.0M$600.0M$800.0M2018: $403.1M$403.1M20182019: $546.7M$546.7M2019+36%2020: $311.8M$311.8M2020−43%2021: $505.8M$505.8M2021+62%2022: $507.6M$507.6M2022+0%2023: $533.1M$533.1M2023+5%2024: $705.7M$705.7M2024+32%2025: $682.9M$682.9M2025−3%
Net income9101112136$374.9M in 2025+168% since 2018
0$1.0B$2.0B$3.0B2018: $139.9M$139.9M20182019: $466.7M$466.7M2019+234%2020: $238.4M$238.4M2020−49%2021: $2.9B$2.9B2021+1135%2022: $385.8M$385.8M2022−87%2023: $294.2M$294.2M2023−24%2024: $392.3M$392.3M2024+33%2025: $374.9M$374.9M2025−4%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2025-10-312024-10-312023-10-31
Net sales$4.1B$3.9B$3.6B
Cost of sales$1.4B$1.3B$1.2B
Gross profit$2.7B$2.6B$2.4B
Selling, general and administrative expense$1.6B$1.5B$1.5B
Research and development expense$172.2M$155.1M$137.4M
Amortization of intangibles$199.2M$201.2M$186.2M
Operating income$682.9M$705.7M$533.1M
Interest expense$100.0M$114.3M$105.3M
Other expense$16.4M$9.1M$14.9M
Income before income taxes$566.5M$582.3M$412.9M
Provision for income taxes (Note 6)$191.6M$190.0M$118.7M
Net income$374.9M$392.3M$294.2M
Basic (in dollars per share)$1.88$1.97$1.49
Diluted (in dollars per share)$1.87$1.96$1.48
Basic (in shares)199.1M shares198.9M shares197.9M shares
Diluted (in shares)200.0M shares200.4M shares199.3M shares

Compare The Cooper Companies with another company

The story

Parker Montgomery, a lawyer, bought Martin H. Smith Co. in 1958. The company was renamed to Cooper, Tinsley Laboratories, Inc. in 1961. Its name was changed to Cooper Laboratories Inc. in 1967, and entered the contact lens business when it acquired British lens maker GlobalVision in 1972.

In 1980, Cooper Laboratories reorganized into three business groups: CooperVision, CooperCare and CooperBiomedical, with Cooper Medical Devices Corp. added as a fourth group one year later.

The company was renamed The Cooper Companies in 1987. Three years later, it was further restructured into three business units: CooperVision, CooperSurgical and CooperVision Pharmaceuticals (dissolved in 2003).

Currently, the firm operates as two business units: CooperVision and CooperSurgical. CooperVision serves contact lens wearers and eye care practitioners. Products include a range of daily, two-week and monthly disposable contact lenses, and other spherical, toric and multifocal lenses for astigmatism, nearsightedness and farsightedness, and presbyopia.

CooperSurgical is the medical device and fertility and genomics unit of the companies. It became a business unit in 1990 and its focus includes women's health and fertility. It is headquartered in Trumbull, Connecticut.

From Wikipedia’s article on The Cooper Companies, shared under CC BY-SA 4.0.8

Leadership

Who has led The Cooper Companies, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. A. Thomas Bender2006–2007
  2. Nicholas J. Pichotta2006–2014
  3. Robert S. Weiss2008–2018
  4. Paul L. Remmell2012–2017
  5. Albert G. White Iii.2018–2020
  6. Robert D. Auerbach2020–2021

President

  1. A. Thomas Bender2006–2007
  2. Andrew Sedgwick2007–2009
  3. Jeffrey Alan McLean2007–2008
  4. Robert S. Weiss2008–2018
  5. Albert G. White Iii.2018
  6. Robert D. Auerbach2018–2020
  7. Holly R. Sheffield2020–2022
  8. Gerard H. Warner Iii.2022–now

Chief financial officer

  1. John J. Calcagno2006–2007
  2. Steven M. Neil2006–2008
  3. Paul L. Remmell2006–2008
  4. Eugene J. Midlock2008–2011
  5. Gregory W. Matz2011–2016
  6. Albert G. White Iii.2016–2018
  7. Brian G. Andrews2018–now

Chief operating officer

  1. Robert S. Weiss2006–2007
  2. Gregory A. Fryling2006
  3. Paul L. Remmell2008–2012
197019801990200020102020
Board members and other officers (35)

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Acquisitions

Ocular Sciences Inc. was acquired by CooperVision in 2005.

CooperSurgical acquired AEGEA Medical, a medical manufacturing company in February 2021. A month later, in March, the company acquired Safe Obstetric Systems, and in December 2021, CooperSurgical acquired Generate Life Sciences for $1.6 billion.

In March 2022, CooperSurgical acquired Cook Medical's reproductive health business for $875 million. During that same year the company acquired EnsEyers, a supplier of orthokeratology and scleral contact lenses.

From Wikipedia’s article on The Cooper Companies, shared under CC BY-SA 4.0.8

Former names

  • COOPER COMPANIES INCAug 1, 1994 to Jun 26, 20197

Timeline

  1. Oct 9, 2020New chief executive Robert D. Auerbach becomes CEO17
  2. May 3, 2018New chief executive Albert G. White Iii. becomes CEO18
  3. Feb 3, 2012New chief executive Paul L. Remmell becomes CEO19
  4. Sep 23, 2008New chief executive Robert S. Weiss becomes CEO20
  5. Oct 26, 2006New chief executive Nicholas J. Pichotta becomes CEO22
  6. Jul 10, 2006New chief executive A. Thomas Bender becomes CEO21
  7. 1958Founded Founded1

Filings

295 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 44 major events, 166 insider forms, 17 large holders, 48 other. The latest 20:

  1. Sep 17, 20264 PRIMARY DOCUMENT EDGAR
  2. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  3. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  4. Sep 15, 20264 PRIMARY DOCUMENT EDGAR
  5. Sep 9, 202610-Q EDGAR
  6. Sep 9, 20268-K EDGAR
  7. Jul 6, 20264 PRIMARY DOCUMENT EDGAR
  8. Jul 6, 20263 PRIMARY DOCUMENT EDGAR
  9. Jun 5, 202610-Q EDGAR
  10. Jun 4, 20268-K EDGAR
  11. May 29, 2026SD EDGAR
  12. May 14, 2026SCHEDULE 13G/A EDGAR
  13. May 4, 20268-K EDGAR
  14. Apr 29, 2026SCHEDULE 13G EDGAR
  15. Apr 21, 20264 PRIMARY DOCUMENT EDGAR
  16. Apr 8, 20268-K EDGAR
  17. Apr 6, 20264 PRIMARY DOCUMENT EDGAR
  18. Apr 6, 20264 PRIMARY DOCUMENT EDGAR
  19. Apr 6, 20264 PRIMARY DOCUMENT EDGAR
  20. Apr 6, 20264 PRIMARY DOCUMENT EDGAR

The 295 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

35 open-market trades by officers, directors and large owners since October 2021: 15 buys and 20 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 16, 2026Kurzius Lawrence ErikDirectorBuy10,000$54.93$549.3KForm 4
Sep 14, 2026Rosebrough Walter M JrDirectorBuy3,000$54.29$162.9KForm 4
Sep 14, 2026Kurzius Lawrence ErikDirectorBuy10,000$53.92$539.2KForm 4
Sep 11, 2026Keel Paul ADirectorBuy4,701$53.18$250.0KForm 4
Sep 11, 2026Rosebrough Walter M JrDirectorBuy7,000$54.11$378.8KForm 4
Dec 22, 2025Lucchese Cynthia LDirectorBuy1,784$84.06$150.0KForm 4
Dec 18, 2025Rivas MariaDirectorBuy1,000$82.13$82.1KForm 4
Dec 17, 2025Kurzius Lawrence ErikDirectorBuy2,000$82.50$165.0KForm 4
Dec 16, 2025Sheffield Holly RPresident, CSIBuy1,230$80.75$99.3KForm 4
Dec 16, 2025White Albert G IIIPresident & CEOBuy10,000$80.80$808.0KForm 4
Sep 29, 2025Kurzius Lawrence ErikDirectorBuy2,000$68.39$136.8KForm 4
Sep 5, 2025White Albert G IIIPresident & CEOBuy10,000$68.39$683.9KForm 4
Sep 5, 2025Warner Gerard H IIIPresident, CooperVision, Inc.Buy1,450$69.23$100.4KForm 4
Sep 2, 2025McBride Daniel GEVP & Chief Operating OfficerBuy3,000$65.04$195.1KForm 4
Sep 2, 2025Andrews Brian GEVP, CFO & TreasurerBuy1,525$65.68$100.2KForm 4
Sep 19, 2024White Albert G IIIPresident & CEOSale114,992$110.53$12.7MForm 4
Sep 10, 2024Ricupati AgostinoSVP & CAOSale1,601$108.03$173.0KForm 4
Sep 5, 2024Andrews Brian GEVP, CFO & TreasurerSale24,788$105.90$2.6MForm 4
Sep 4, 2024McBride Daniel GEVP & Chief Operating OfficerSale114,992$105.48$12.1MForm 4
Mar 18, 2024Ricupati AgostinoSVP & CAOSale54,724$100.89$5.5MForm 4

All 35 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.15,029,453$1.1B0.0%−1,588,676
Vanguard Capital Management LLC12,758,769$914.9M0.0%+39,940
State Street Corp8,892,643$637.7M0.0%+124,224
Vanguard Portfolio Management LLC8,669,690$621.7M0.0%−51,641
Browning West LP7,195,428$516.0M30.5%+215,899
Kayne Anderson Rudnick Investment Management LLC5,430,282$389.4M1.2%−1,186,395
Geode Capital Management, LLC5,359,812$382.9M0.0%+48,289
Franklin Resources Inc5,096,888$365.5M0.1%+229,606
Generation Investment Management Llp4,968,673$356.3M3.5%+369,284
Jupiter Topco LLC4,254,267$305.1M0.1%New
Arrowstreet Capital, Limited Partnership4,004,357$287.2M0.1%+1,878,057
Aqr Capital Management LLC4,022,614$285.7M0.1%+295,427
Longview Partners (Guernsey) LTD3,940,007$282.5M4.6%+116,945
UBS Group AG3,932,013$282.0M0.0%+496,795
Citadel Advisors LLC3,872,397$277.7M0.2%+3,679,872
Invesco Ltd.3,685,038$264.3M0.0%+28,227
JANA Partners Management, LP3,582,480$256.9M13.5%+17,322
Wellington Management Group Llp3,468,951$248.8M0.0%+103,044
Dimensional Fund Advisors LP3,341,607$239.6M0.0%+1,272,730
London Co Of Virginia2,898,075$207.8M1.2%+660,930
Diamond Hill Capital Management, LLC (Investment Advisor)2,731,198$195.9M1.6%−667,062
Massachusetts Financial Services Co /ma/2,343,776$187.8M0.1%−274,504
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,549,015$182.8M0.0%+18,946
Barclays PLC2,120,075$152.0M0.0%+1,787,487
Bank Of America Corp /de/2,009,835$144.1M0.0%+571,722

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

6 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Jun 5, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−18.6%Report
May 29, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−7.4%Report
Mar 27, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000−38.7%Report
Dec 10, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−40.5%Report
May 15, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000+59.6%Report
Jan 5, 2017Thomas R. SuozziDemocratic, HouseSale$15,001 - $50,000+209.5%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76